What is claimed is:

1. A compound of Formula I:



I

wherein:

X is selected from C_1-C_8 alkyl, halo, -OR^{10}, -$NR^{14}R^{15}$, nitro, cyano, -$COOR^{10}$, -COR^{13}, -$OCOR^{13}$, -$N(R^{17})COR^{13}$, -$N(R^{17})CONR^{14}R^{15}$, -$N(R^{17})COOR^{13}$, -SO_3H, -$SO_2NR^{14}R^{15}$, -$C(=NR^{17})NR^{14}R^{15}$, -$N(R^{17})SO_2R^{16}$, and a 5 or 6-membered heterocyclic group;

or X and an adjacent R^3, taken together with the atoms to which they are bonded, form an alkylenedioxy moiety;

Z is CH, CR^3 or N, wherein when Z is CH or CR^3, k is 0-4 and t is 0 or 1, and when Z is N, k is 0-3 and t is 0;

Y is selected from -O-, -S-, -$N(R^{10})$-, and -$C(R^4)(R^5)$-;

W^1 is selected from C_1-C_8 alkyl, C_3-C_8 cycloalkyl, aryl and Het, wherein said C_1-C_8 alkyl, C_3-C_8 cycloalkyl, Ar and Het are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-CO_2R^{10}, -C_0-C_6 alkyl-$C(O)SR^{10}$, -C_0-C_6 alkyl-$CONR^{11}R^{12}$, -C_0-C_6 alkyl-COR^{13}, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-SR^{10}, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-SO_3H, -C_0-C_6 alkyl-$SO_2NR^{11}R^{12}$, -C_0-C_6 alkyl-SO_2R^{10}, -C_0-C_6 alkyl-SOR^{13}, -C_0-C_6 alkyl-$OCOR^{13}$, -C_0-C_6 alkyl-$OC(O)NR^{11}R^{12}$, -C_0-C_6 alkyl-$OC(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)NR^{11}R^{12}$, and -C_0-C_6 alkyl-$NR^{11}COR^{13}$, where said C_1-C_6 alkyl, is optionally unsubstituted or substituted by one or more halo substituents;

W^2 is selected from H, halo, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-SR^{10}, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-CO_2R^{10}, -C_0-C_6 alkyl-$C(O)SR^{10}$, -C_0-C_6 alkyl-$CONR^{11}R^{12}$, -C_0-C_6 alkyl-COR^{13}, -C_0-C_6 alkyl-$OCOR^{13}$, -C_0-C_6 alkyl-$OCONR^{11}R^{12}$, -C_0-C_6 alkyl-$NR^{11}CONR^{11}R^{12}$, -C_0-C_6 alkyl-$NR^{11}COR^{13}$, -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-Ar and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl, wherein said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents, and wherein the C_3-C_7 cycloalkyl, Ar and Het moieties of said -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-Ar and

$-C_0-C_6$ alkyl-C_3-C_7 cycloalkyl are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, $-C_0-C_6$ alkyl-CO_2R^{10}, $-C_0-C_6$ alkyl-$C(O)SR^{10}$, $-C_0-C_6$ alkyl-$CONR^{11}R^{12}$, $-C_0-C_6$ alkyl-COR^{13}, $-C_0-C_6$ alkyl-$NR^{11}R^{12}$, $-C_0-C_6$ alkyl-SR^{10}, $-C_0-C_6$ alkyl-OR^{10}, $-C_0-C_6$ alkyl-SO_3H, $-C_0-C_6$ alkyl-$SO_2NR^{11}R^{12}$, $-C_0-C_6$ alkyl-SO_2R^{10}, $-C_0-C_6$ alkyl-SOR^{13}, $-C_0-C_6$ alkyl-$OCOR^{13}$, $-C_0-C_6$ alkyl-$OC(O)NR^{11}R^{12}$, $-C_0-C_6$ alkyl-$OC(O)OR^{13}$, $-C_0-C_6$ alkyl-$NR^{11}C(O)OR^{13}$, $-C_0-C_6$ alkyl-$NR^{11}C(O)NR^{11}R^{12}$, and $-C_0-C_6$ alkyl-$NR^{11}COR^{13}$, where said C_1-C_6 alkyl, is optionally unsubstituted or substituted by one or more halo substituents;

W^3 is selected from the group consisting of: H, halo, C_1-C_6 alkyl, $-C_0-C_6$ alkyl-$NR^{11}R^{12}$, $-C_0-C_6$ alkyl-SR^{10}, $-C_0-C_6$ alkyl-OR^{10}, $-C_0-C_6$ alkyl-CO_2R^{10}, $-C_0-C_6$ alkyl-$C(O)SR^{10}$, $-C_0-C_6$ alkyl-$CONR^{11}R^{12}$, $-C_0-C_6$ alkyl-COR^{13}, $-C_0-C_6$ alkyl-$OCOR^{13}$, $-C_0-C_6$ alkyl-$OCONR^{11}R^{12}$, $-C_0-C_6$ alkyl-$NR^{11}CONR^{11}R^{12}$, $-C_0-C_6$ alkyl-$NR^{11}COR^{13}$, $-C_0-C_6$ alkyl-Het, $-C_1-C_6$ alkyl-Ar and $-C_1-C_6$ alkyl-C_3-C_7 cycloalkyl, wherein said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents;

Q is selected from C_3-C_8 cycloalkyl, Ar and Het; wherein said C_3-C_8 cycloalkyl, Ar and Het are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, $-C_0-C_6$ alkyl-CO_2R^{10}, $-C_0-C_6$ alkyl-$C(O)SR^{10}$, $-C_0-C_6$ alkyl-$CONR^{11}R^{12}$, $-C_0-C_6$ alkyl-COR^{13}, $-C_0-C_6$ alkyl-$NR^{11}R^{12}$, $-C_0-C_6$ alkyl-SR^{10}, $-C_0-C_6$ alkyl-OR^{10}, $-C_0-C_6$ alkyl-SO_3H, $-C_0-C_6$ alkyl-$SO_2NR^{11}R^{12}$, $-C_0-C_6$ alkyl-SO_2R^{10}, $-C_0-C_6$ alkyl-SOR^{13}, $-C_0-C_6$ alkyl-$OCOR^{13}$, $-C_0-C_6$ alkyl-$OC(O)NR^{11}R^{12}$, $-C_0-C_6$ alkyl-$OC(O)OR^{13}$, $-C_0-C_6$ alkyl-$NR^{11}C(O)OR^{13}$, $-C_0-C_6$ alkyl-$NR^{11}C(O)NR^{11}R^{12}$, and $-C_0-C_6$ alkyl-$NR^{11}COR^{13}$, where said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents;

p is 0-8;

n is 2-8;

m is 0 or 1;

q is 0 or 1;

t is 0 or 1;

each R^1 and R^2 are independently selected from H, halo, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, $-C_0-C_6$ alkyl-$NR^{11}R^{12}$, $-C_0-C_6$ alkyl-OR^{10}, $-C_0-C_6$ alkyl-SR^{10}, $-C_1-C_6$ alkyl-Het, $-C_1-C_6$ alkyl-Ar and $-C_1-C_6$ alkyl-C_3-C_7 cycloalkyl, or R^1 and R^2 together with the carbon to which they are attached form a 3-5 membered carbocyclic or heterocyclic ring, wherein said heterocyclic ring contains one, or more heteroatoms selected from N, O, and S, where any of said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each R^3 is the same or different and is independently selected from halo, cyano, nitro, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, $-C_0-C_6$ alkyl-Ar, $-C_0-C_6$ alkyl-Het, $-C_0-C_6$ alkyl-C_3-C_7 cycloalkyl, $-C_0-C_6$ alkyl-CO_2R^{10}, $-C_0-C_6$ alkyl-$C(O)SR^{10}$, $-C_0-C_6$ alkyl-$CONR^{11}R^{12}$, $-C_0-C_6$ alkyl-COR^{13}, $-C_0-C_6$ alkyl-$NR^{11}R^{12}$, $-C_0-C_6$ alkyl-SR^{10},

$-C_0-C_6$ alkyl-OR^{10}, $-C_0-C_6$ alkyl-SO_3H, $-C_0-C_6$ alkyl-$SO_2NR^{11}R^{12}$, $-C_0-C_6$ alkyl-SO_2R^{10}, $-C_0-C_6$ alkyl-SOR^{13}, $-C_0-C_6$ alkyl-$OCOR^{13}$, $-C_0-C_6$ alkyl-$OC(O)NR^{11}R^{12}$, $-C_0-C_6$ alkyl-$OC(O)OR^{13}$, $-C_0-C_6$ alkyl-$NR^{11}C(O)OR^{13}$, $-C_0-C_6$ alkyl-$NR^{11}C(O)NR^{11}R^{12}$, and $-C_0-C_6$ alkyl-$NR^{11}COR^{13}$, wherein said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each R^4 and R^5 is independently selected from H, halo, C_1-C_6 alkyl, $-C_0-C_6$ alkyl-Het, $-C_0-C_6$ alkyl-Ar and $-C_0-C_6$ alkyl-C_3-C_7 cycloalkyl;

R^6 and R^7 are each independently selected from H, halo, C_1-C_6 alkyl, $-C_0-C_6$ alkyl-Het, $-C_0-C_6$ alkyl-Ar and $-C_0-C_6$ alkyl-C_3-C_7 cycloalkyl;

R^8 and R^9 are each independently selected from H, halo, C_1-C_6 alkyl, $-C_0-C_6$ alkyl-Het, $-C_0-C_6$ alkyl-Ar and $-C_0-C_6$ alkyl-C_3-C_7 cycloalkyl;

R^{10} is selected from H, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, $-C_0-C_6$ alkyl-Ar, $-C_0-C_6$ alkyl-Het and $-C_0-C_6$ alkyl-C_3-C_7 cycloalkyl;

each R^{11} and each R^{12} are independently selected from H, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, $-C_0-C_6$ alkyl-Ar, $-C_0-C_6$ alkyl-Het and $-C_0-C_6$ alkyl-C_3-C_7 cycloalkyl, or R^{11} and R^{12} together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S;

R^{13} is selected from C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, $-C_0-C_6$ alkyl-Ar, $-C_0-C_6$ alkyl-Het and $-C_0-C_6$ alkyl-C_3-C_7 cycloalkyl;

R^{14} and R^{15} are each independently selected from H, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, $-C_0-C_6$ alkyl-Ar, $-C_0-C_6$ alkyl-Het, $-C_0-C_6$ alkyl-C_3-C_7 cycloalkyl, $-C_0-C_6$ alkyl-O-Ar, $-C_0-C_6$ alkyl-O-Het, $-C_0-C_6$ alkyl-O-C_3-C_7 cycloalkyl, $-C_0-C_6$ alkyl-$S(O)_x-C_1-C_6$ alkyl, $-C_0-C_6$ alkyl-$S(O)_x$-Ar, $-C_0-C_6$ alkyl-$S(O)_x$-Het, $-C_0-C_6$ alkyl-$S(O)_x-C_3-C_7$ cycloalkyl, $-C_0-C_6$ alkyl-NH-Het, $-C_0-C_6$ alkyl-NH-C_3-C_7 cycloalkyl, $-C_0-C_6$ alkyl-$N(C_1-C_4$ alkyl)-Ar, $-C_0-C_6$ alkyl-$N(C_1-C_4$ alkyl)-Het, $-C_0-C_6$ alkyl-$N(C_1-C_4$ alkyl)-C_3-C_7 cycloalkyl, $-C_0-C_6$ alkyl-Ar, $-C_0-C_6$ alkyl-Het and $-C_0-C_6$ alkyl-C_3-C_7 cycloalkyl, where x is 0, 1 or 2, or R^{14} and R^{15}, together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S, wherein said C_1-C_6 alkyl is optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, $-NH_2$, -NH(unsubstituted C_1-C_6 alkyl), -N(unsubstituted C_1-C_6 alkyl)(unsubstituted C_1-C_6 alkyl), unsubstituted $-OC_1-C_6$ alkyl, $-CO_2H$, $-CO_2$(unsubstituted C_1-C_6 alkyl), $-CONH_2$, -CONH(unsubstituted C_1-C_6 alkyl), -CON(unsubstituted C_1-C_6 alkyl)(unsubstituted C_1-C_6 alkyl), $-SO_3H$, $-SO_2NH_2$, $-SO_2NH$(unsubstituted C_1-C_6 alkyl) and $-SO_2N$(unsubstituted C_1-C_6 alkyl)(unsubstituted C_1-C_6 alkyl);

R^{16} is C_1-C_6 alkyl, $-C_0-C_6$ alkyl-Ar or $-C_0-C_6$ alkyl-Het; and

R^{17} is H, C_1-C_6 alkyl, $-C_0-C_6$ alkyl-Ar or $-C_0-C_6$ alkyl-Het;

provided that X is not $COOR^{10}$ when Y is -O-, p is 0-8, n is 2-8, m is 1, q is 0 or 1, t is 0, each R^1 and R^2 is independently selected from H, C_1-C_6 alkyl, -OH, -O-C_1-C_6 alkyl, -SH, and -S-C_1-C_6 alkyl, each R^4, R^5, R^6, R^7, R^8 and R^9 are independently H or C_1-C_4 alkyl, k is 0 or 1, W^3 is H, W^1 and W^2 are each independently selected from C_3-C_8 cycloalkyl and aryl and R^3 and Q are as defined above; or

provided that the compound is not

5-[3-[[(3,4-dichlorophenyl)methyl][2-(2-naphthalenyl)ethyl]amino]propoxy]-3-methoxy-1,2-benzenedicarboxylic acid

5-[3-[[(3,4-dichlorophenyl)methyl][2-(2-naphthalenyl)ethyl]amino]propoxy]-3-methoxy-1,2-benzenedicarboxylic acid, dimethyl ester

4-[[[2-(4-carboxyphenoxy)ethyl][2-[2-[(5-phenylpentyl)oxy]phenyl]ethyl]amino]methyl] benzoic acid

4-[[[2-[4-(ethoxycarbonyl)phenoxy]ethyl][2-[2-(octyloxy)phenyl]ethyl]amino]methyl]-benzoic acid methyl ester,

4-[[[2-(4-carboxyphenoxy)ethyl][2-[2-(octyloxy)phenyl]ethyl]amino]methyl], benzoic acid,

α-[[[3-(4-fluorophenyl)-1,1-dimethylpropyl](phenylmethyl)amino]methyl]-3-(phenylmethoxy)-benzenemethanol hydrochloride,

N-[2-(4-amino-3,5-dichlorophenyl)ethyl]-4-fluoro-N-(phenylmethyl)-benzenepropanamine monohydrochloride,

N-[2-(4-amino-3,5-dichlorophenyl)ethyl]-4-chloro-N-(phenylmethyl)-benzenepropanamine monohydrochloride,

4-amino-3,5-dichloro-α-[[[3-(4-fluorophenyl)propyl](phenylmethyl)amino]methyl]-benzenemethanol monohydrochloride,

4-amino-3,5-dichloro-α-[[[3-(4-chlorophenyl)propyl](phenylmethyl)amino]methyl]-benzenemethanol monohydrochloride,

2-chloro-5-[2-[[3-(4-fluorophenyl)-1-methylpropyl](phenylmethyl)amino]-1-hydroxyethyl]-benzamide monohydrochloride,

4-[2-[[2-hydroxy-2-[4-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethoxy]-benzeneacetamide,

4-[2-[[2-[3,4-bis(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethoxy]-benzenesulfonamide monohydrochloride,

(R)-3-(phenylmethoxy)-α-[[[3-[3-(phenylmethoxy)phenyl]propyl](phenylmethyl)amino]methyl]-benzenemethanol

2,2-dichloro-acetic acid (R)-{benzyl-[3-(3-benzyloxy-phenyl)-propyl]-amino}-(3-benzyloxy-phenyl)-ethyl ester,

3-amino-α-[[[3-(3,4-dimethoxyphenyl)-1-methylpropyl](phenylmethyl)amino]methyl]-4-(phenylmethoxy)-benzenemethanol,

α-[[[3-(3,4-dimethoxyphenyl)-1-methylpropyl](phenylmethyl)amino]methyl]-3-nitro-4-(phenylmethoxy)-benzenemethanol,

α-[[[3-(3,4-dimethoxyphenyl)-1-methylpropyl](phenylmethyl)amino]methyl]-3-nitro-5-(phenylmethoxy)-benzenemethanol,

3-amino-α-[[[3-(3,4-dimethoxyphenyl)-1-methylpropyl](phenylmethyl)amino]methyl]-5-(phenylmethoxy)-benzenemethanol, or

4-[2-[[2-(4-fluorophenoxy)ethyl](phenylmethyl)amino]ethyl]-1-piperazineacetic acid ethyl ester;

or a pharmaceutically acceptable salt or solvate thereof.

2. The compound according to claim 1, wherein p is 0, 1 or 2.

3. The compound according to claim 1, wherein t is 0.

4. The compound according to any one of claims 1-3, wherein R^1 and R^2 are independently H or C_1-C_4 alkyl or R^1 and R^2 together with the carbon to which they are attached form a 3-5 membered carbocyclic ring.

5. The compound according to any one of claims 1-4, wherein k is 0 or 1.

6. The compound according to any one of claims 1-5, wherein R^3 is selected from halo, C_1-C_4 alkyl and C_1-C_4 alkoxy.

7. The compound according to any one of claims 1-6, wherein X is selected from C_1-C_6 alkyl, halo, $-OR^{10}$, $-NR^{14}R^{15}$, cyano, $-COR^{13}$, $-COOR^{10}$, $-OCOR^{13}$, $-N(R^{17})CONR^{14}R^{15}$, $-N(R^{17})COR^{13}$, $-SO_2NR^{14}R^{15}$, $-N(R^{17})SO_2R^{16}$, and a 5 or 6-membered heterocyclic group or X and an adjacent R^3, taken together with the atoms to which they are bonded, form an alkylenedioxy moiety.

8. The compound according to any claim 7, wherein R^{10} is H, C_1-C_4 alkyl or phenyl; R^{13} is H, C_1-C_4 alkyl, $-C_0$-C_4 alkyl-C_3-C_7 cycloalkyl, or $-C_0$-C_4 alkyl-phenyl; R^{14} and R^{15} are each independently selected from H, C_1-C_6 alkyl, $-C_0$-C_4 alkyl-Ar, $-C_0$-C_4 alkyl-Het, $-C_0$-C_4 alkyl-C_3-C_7 cycloalkyl, $-C_0$-C_4 alkyl-O-Ar, $-C_0$-C_4 alkyl-O-Het, $-C_0$-C_4 alkyl-O-C_3-C_7 cycloalkyl, $-C_0$-C_4 alkyl-$S(O)_2$-C_1-C_4 alkyl, $-C_0$-C_4 alkyl-$S(O)_2$-Ar, $-C_0$-C_4 alkyl-$S(O)_2$-Het, $-C_0$-C_4 alkyl-$S(O)_2$-C_3-C_7 cycloalkyl, $-C_0$-C_4 alkyl-NH-Ar, $-C_0$-C_4 alkyl-NH-Het, $-C_0$-C_4 alkyl-NH-C_3-C_7 cycloalkyl, $-C_0$-C_4 alkyl-N(C_1-C_4 alkyl)-Ar, $-C_0$-C_4 alkyl-N(C_1-C_4 alkyl)-Het, $-C_0$-C_4 alkyl-N(C_1-C_4 alkyl)-C_3-C_7 cycloalkyl, $-C_0$-C_4 alkyl-Ar, $-C_0$-C_4 alkyl-Het and $-C_0$-C_4 alkyl-C_3-C_7 cycloalkyl, or R^{14} and R^{15}, together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S, wherein said C_1-C_6 alkyl is

optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, $-NH_2$, -NH(unsubstituted C_1-C_4 alkyl), -N(unsubstituted C_1-C_4 alkyl)(unsubstituted C_1-C_4 alkyl), unsubstituted -OC_1-C_4 alkyl, $-CO_2H$, $-CO_2$(unsubstituted C_1-C_4 alkyl), $-CONH_2$, -CONH(unsubstituted C_1-C_4 alkyl), -CON(unsubstituted C_1-C_4 alkyl)(unsubstituted C_1-C_4 alkyl), $-SO_3H$, $-SO_2NH_2$, $-SO_2$NH(unsubstituted C_1-C_4 alkyl) and $-SO_2$N(unsubstituted C_1-C_4 alkyl)(unsubstituted C_1-C_4 alkyl); R^{16} is C_1-C_4 alkyl or phenyl; and R^{17} is H or C_1-C_4 alkyl.

8. The compound according to any one of claims 1-7 wherein n is 3.

9. The compound according to any one of claims 1-8, wherein q is 1.

10. The compound according to any one of claims 1-9, wherein R^8 and R^9 are each H.

11. The compound according to any one of claims 1-10, wherein Q is a substituted or unsubstituted phenyl or furanyl group or a benzo[1,3]dioxyl or benzo[1,4]dioxyl group containing one, two or three substituents selected from halo, C_1-C_4 alkyl; C_1-C_4 alkylthio; or $-NR^{Q1}R^{Q2}$, where R^{Q1} and R^{Q2} taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may optionally contain one or more additional heteroatoms selected form N, O and S.

12. The compound according to claim 11, wherein said substituents are selected from fluoro, chloro, trifluoromethyl, tert-butyl, isopropyl, methylthio and piperidin-1-yl.

13. The compound according to any one of claims 1-12, wherein m is 0 or m is 1 and R^6 and R^7 are each H.

14. The compound according to any one of claims 1-13, wherein W^1 is phenyl, naphthyl, thienyl, pyridyl, furanyl, pyrrolyl, cyclohexyl, cyclopentyl, morpholinyl, or pyrrolidinyl, where each phenyl, naphthyl, thienyl, pyridyl, furanyl, pyrrolyl, cyclohexyl, cyclopentyl, morpholinyl, or pyrrolidinyl may be optionally substituted from 1 to 3 times with one or more of the substituents independently selected from C_1-C_4 alkyl, -OH, halo, -O-C_1-C_4 alkyl, and -C_1-C_4 haloalkyl.

15. The compound according to any one of claims 1-14, wherein W^2 is C_1-C_4 alkyl, C_2-C_4 alkynyl, C_3-C_6 cycloalkyl, aryl, Het hydroxy, aryloxy-, C_1-C_4 alkoxy-, -$OCOC_1$-C_4 alkyl, -OCOaryl, or $-NR^{W1}R^{W2}$, where R^{W1} and R^{W2} are independently H or C_1-C_4 alkyl or taken together with the nitrogen to which they are attached form a 4-7

membered heterocyclic ring, which may optionally contain one or more additional heteroatoms selected form N, O and S.

16. The compound according to any one of claims 1-15, wherein W^3 is H or C_1-C_4 alkyl.

17. The compound according to claim 1, wherein X is selected from C_1-C_6 alkyl, halo, $-OR^{10}$, $-NR^{14}R^{15}$, cyano, $-COR^{13}$, $-COOR^{10}$, $-OCOR^{13}$, $-N(R^{17})CONR^{14}R^{15}$, $-N(R^{17})COR^{13}$, $-SO_2NR^{14}R^{15}$, $-N(R^{17})SO_2R^{16}$, and a 5 or 6-membered heterocyclic group or X and an adjacent R^3, taken together with the atoms to which they are bonded, form an alkylenedioxy moiety, where R^{10} is H, C_1-C_4 alkyl or phenyl, R^{13} is H, C_1-C_4 alkyl, $-C_0$-C_4 alkyl-C_3-C_7 cycloalkyl, or $-C_0$-C_4 alkyl-phenyl, R^{14} and R^{15} are each independently selected from H, C_1-C_6 alkyl, $-C_0$-C_4 alkyl-Ar, $-C_0$-C_4 alkyl-Het, $-C_0$-C_4 alkyl-C_3-C_7 cycloalkyl, $-C_0$-C_4 alkyl-O-Ar, $-C_0$-C_4 alkyl-O-Het, $-C_0$-C_4 alkyl-O-C_3-C_7 cycloalkyl, $-C_0$-C_4 alkyl-$S(O)_2$-C_1-C_4 alkyl, $-C_0$-C_4 alkyl-$S(O)_2$-Ar, $-C_0$-C_4 alkyl-$S(O)_2$-Het, $-C_0$-C_4 alkyl-$S(O)_2$-C_3-C_7 cycloalkyl, $-C_0$-C_4 alkyl-NH-Ar, $-C_0$-C_4 alkyl-NH-Het, $-C_0$-C_4 alkyl-NH-C_3-C_7 cycloalkyl, $-C_0$-C_4 alkyl-N(C_1-C_4 alkyl)-Ar, $-C_0$-C_4 alkyl-N(C_1-C_4 alkyl)-Het, $-C_0$-C_4 alkyl-N(C_1-C_4 alkyl)-C_3-C_7 cycloalkyl, $-C_0$-C_4 alkyl-Ar, $-C_0$-C_4 alkyl-Het and $-C_0$-C_4 alkyl-C_3-C_7 cycloalkyl, or R^{14} and R^{15}, together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S, wherein said C_1-C_6 alkyl is optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, $-NH_2$, -NH(unsubstituted C_1-C_4 alkyl), -N(unsubstituted C_1-C_4 alkyl)(unsubstituted C_1-C_4 alkyl), unsubstituted $-OC_1$-C_4 alkyl, $-CO_2H$, $-CO_2$(unsubstituted C_1-C_4 alkyl), $-CONH_2$, -CONH(unsubstituted C_1-C_4 alkyl), -CON(unsubstituted C_1-C_4 alkyl)(unsubstituted C_1-C_4 alkyl), $-SO_3H$, $-SO_2NH_2$, $-SO_2$NH(unsubstituted C_1-C_4 alkyl) and $-SO_2$N(unsubstituted C_1-C_4 alkyl)(unsubstituted C_1-C_4 alkyl), R^{16} is C_1-C_4 alkyl or phenyl, and R^{17} is H or C_1-C_4 alkyl; p is 0, 1 or 2; R^1 and R^2 are independently H or C_1-C_4 alkyl or R^1 and R^2 together with the carbon to which they are attached form a 3-5 membered carbocyclic ring; k is 0 or k is 1 and R^3 is halo, C_1-C_4 alkyl or C_1-C_4 alkoxy; n is 3 and each R^4 and R^5 are independently selected from H and C_1-C_3 alkyl; Z is CH or N; Y is -O- or $-C(R^4)(R^5)-$; q is 1; R^8 and R^9 are each H; Q is a substituted or unsubstituted phenyl or furanyl group or a benzo[1,3]dioxyl or benzo[1,4]dioxyl group, where the substituted phenyl or furanyl group contains one, two or three substituents selected from halo, C_1-C_4 alkyl; C_1-C_4 alkylthio; or $-NR^{Q1}R^{Q2}$, where R^{Q1} and R^{Q2} taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may optionally contain one or more additional heteroatoms selected form N, O and S; t is 0 or 1; m is 0 or 1; R^6 and R^7 are independently selected from H and C_1-C_4 alkyl; W^1 is methyl, unsubstituted phenyl, naphthyl, pyridyl, thienyl or pyrrolyl or substituted phenyl or pyridyl containing one or two substituents independently selected from

halo, alkyl and alkoxy, specifically, chloro, methyl and methoxy; W^2 is C_1-C_4 alkyl, C_2-C_4 alkynyl, C_3-C_6 cycloalkyl, aryl, Het hydroxy, aryloxy-, C_1-C_4 alkoxy-, -OCOC_1-C_4 alkyl, -OCOaryl, or -$NR^{W1}R^{W2}$, where R^{W1} and R^{W2} are independently H or C_1-C_4 alkyl or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may optionally contain one or more additional heteroatoms selected form N, O and S; W^3 is H or C_1-C_4 alkyl; or a pharmaceutically acceptable salt or solvate thereof.

18. The compound according to claim 1, wherein X is chloro, bromo, cyano, carboxy-, methylcarboxy-, hydroxy, methoxy, methyl, trifluoromethyl, 1,3-dihydroxy-prop-2-yl (-$CH(CH_2OH)_2$, isopropyl, n-butyl, isobutyl, 2,2-dimethylpropyl, phenylcarbonyl, triazolyl, tetrazolyl, -NH_2, -$NHCH_3$, -$NHCH_2CH_3$, -$NHCH_2CH_2CH_3$, -$NHCH_2CH_2CH_2CH_3$, -$NHCH_2CH_2CH_2CH_2CH_2CH_3$, -$NHCH_2C(CH_3)_3$, -$NHCH_2CH(CH_3)_2$, -$NHCH_2CH_2CH(CH_3)_2$, -NH-cyclopentyl, -NH-phenyl, -$NHCH_2$-cyclopropyl, -$NHCH(CH_3)_2$, -$NHCH_2CF_3$, -$N(CH_3)_2$, -$N(CH_2CH_3)_2$, -$NHCH(CH_2CH_3)_2$, -$NHCH_2CH(CH_2CH_3)_2$, -$NHCH_2CH_2OH$, -$NHCH_2CO_2H$, -$N(CH_3)CH_2CO_2H$, -$NHC(CH_3)_2CO_2H$, -$NHCH(CH_3)CO_2H$, -(R)-$NHCH(CH_3)CO_2H$, -(S)-$NHCH(CH_3)CO_2H$, -$NHCH_2$-1H-imidazol-2-yl, -$NHCH_2$-(1-CH_3-imidazol-2-yl, -NH-(pyrimidin-2-yl), -morpholin-4-yl, -thiomorpholin-4-yl, -piperidin-1-yl, -piperidin-1-yl-(4-carboxylic acid), -piperidin-1-yl-(4-acetic acid), -piperidin-4-yl-(1-acetic acid), -2,5-dimethyl-pyrrol-1-yl, -pyrrolidin-1-yl, -((R)-2-CO_2H-pyrrolidin-1-yl), -((S)-2-CO_2H-pyrrolidin-1-yl), -piperazin-1-yl, -(4-methyl-piperazin-1-yl), -piperazin-1-yl-(4-acetic acid), -$NHCH_2$-(5-bromo-thien-2-yl), -$NHCH_2$-1H-imidazol-2-yl, -$NHCH_2$-(1-methyl-imidazol-2-yl, -$NHCOCH_3$, -$N(CH_3)COCH_3$, -$NHCO_2C(CH_3)_3$, -$NHCOCH_2CH_3$, -$NHCOC(CH_3)_2$, -NHCO-furan-2-yl, -$N(CH_3)$CO-furan-2-yl, -NHCO-thien-2-yl, -NHCO-cyclopropyl, -NHCO-(5-bromo-thien-2-yl, -NHCO-(2,5-dimethyl-pyrrol-3-yl), -$NHSO_2CH_3$, -$N(CH_3)SO_2CH_3$, -$NHSO_2CF_3$, -$NHSO_2$phenyl, -$N(CH_3)SO_2$phenyl, -$NHSO_2CH_2CH_3$, -$NHSO_2CH_2CF_3$, -$NHSO_2CH_2CH_2CH_3$, -$NHSO_2CH(CH_3)_2$,-NHCONH(2-chlorophenyl), -$N(CH_3)$CONH(3,5-dimethoxyphenyl), -$N(CH_3)$CONH(2-chlorophenyl), -$N(CH_3)$CO-(benzo[1,3]diox-5-yl), -SO_2NHCH_3, and -$SO_2N(CH_3)_2$; p is 0, 1 or 2; R^1 and R^2 are H C_1-C_4 alkyl or R^1 and R^2 together with the carbon to which they are attached form a 3, 4 or 5 membered carbocyclic ring; Z is CH of N; k is 0 or k is 1 and R^3 is methyl, trifluoromethyl, chloro or methoxy; n is 3 and R^4 and R^5 are independently selected from H and methyl; Y is -O- or -C(R^4)(R^5)-; q is 1; R^8 and R^9 are each H; Q is 2-chloro-3-(trifluoromethyl)phenyl, 3-methyl-4-fluoro-phenyl, 4-tert-butyl-phenyl, 4-(methylthio)phenyl, 2,4,5-trifluoro-phenyl, 4-isopropyl-phenyl, 5-(piperidin-1-yl)-furan-2-yl, benzo[1,3]diox-5-yl, or 2,3-dihydrobenzo[1,4]dioxin-6-yl; t is 0 or 1; m is 0 or 1; R^6 and R^7 are independently selected from H and methyl; W^1 is methyl, phenyl, naphth-1-yl, pyrid-2-yl, 4-methyl-pyrid-2-yl, thien-2-yl, thien-3-yl, pyrrol-2-yl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methoxyphenyl, or 4-methoxyphenyl; W^2 is methyl, ethyl, ethynyl, isopropyl, n-butyl, 2-methylpropyl, trifluorormethyl, cyclohexyl, unsubstituted phenyl, hydroxy, methoxy, phenoxy, dimethylamino, morpholin-4-yl,

phenylcarbonyloxy, or methylcarbonyloxy; W^3 is H or methyl; or a pharmaceutically acceptable salt or solvate thereof.

19. A compound selected from:

2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-dephenylethyl)amino]propoxy}phenyl)-ethanol; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}-phenyl)acetic acid, N-oxide; (3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}-bromobenzene; (4-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}-bromobenzene; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenylethyl)-{3-[3-(1,2,4-triazol-3-ylmethyl)-phenoxy]-propyl}-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(1,2,3,4-tetrazol-5-ylmethyl)-phenoxy]-propyl}-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2-cyclohexyl-2-phenyl-ethyl)-{3-[3-(1,2,3,4-tetrazol-5-ylmethyl)-phenoxy]-propyl}-amine; (*S*)-(2-Chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-{3-[3-(1,2,3,4-tetrazol-3-ylmethyl)-phenoxy]-propyl}-amine; (*R*)-(2-Chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-{3-[3-(1,2,3,4-tetrazol-3-ylmethyl)-phenoxy]-propyl}-amine; (*S*)-2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2-phenyl-propyl)amino]propoxy}-phenyl)acetic acid; (*R*)-2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2-phenyl-propyl)amino]propoxy}-phenyl)acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl] naphthalen-1-ylmethyl-amino]propoxy}-phenyl)acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl]-benzylamino]propoxy}-phenyl)acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)-benzyl]phenethylamino]propoxy}-phenyl)acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2-hydroxy-2-phenyl-ethyl)amino]propoxy}-phenyl)acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2-acetoxy-2-phenyl-ethyl)amino]propoxy}-phenyl)acetic acid; 2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-phenoxy-2-phenyl-ethyl)amino]propoxy}-phenyl)acetic acid; Benzoic acid 2-[3-(3-carboxymethyl-phenoxy){2-chloro-3-(trifluoromethyl)benzyl}propylamino]-1-phenyl ethyl ester; (3-{3-[(2-Acetoxy-2-phenyl-ethyl)-(2-chloro-3-trifluoromethyl-benzyl)-amino]-propoxy}-phenyl)-acetic acid methyl ester; Benzoic acid 2-[3-(3-methoxycarbonylmethyl-phenoxy){2-chloro-3-(trifluoromethyl)benzyl}propylamino]-1-phenyl ethyl ester; (3-{4-[(2-Chloro-3-(trifluoromethyl)benzyl)-(2,2-diphenylethyl)-amino]butyl}phenyl)-acetic acid; Preparation of (3-{3-[(4-Fluoro-3-methyl-benzyl)-((R)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-acetic acid; (3-{3-[Benzo[1,3]dioxol-5-ylmethyl-((R)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-acetic acid; (3-{3-[(4-tert-Butyl-benzyl)-((R)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-acetic acid; (3-{3-[(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-((R)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-acetic acid; (3-{3-[(4-Methylsulfanyl-benzyl)-((R)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-acetic acid; (3-{3-[((R)-2-Phenyl-propyl)-(2,4,5-trifluoro-benzyl)-amino]-propoxy}-phenyl)-acetic acid; (3-{3-[((R)-2-Phenyl-propyl)-(5-piperidin-1-yl-furan-2-ylmethyl)-amino]-propoxy}-phenyl)-acetic acid; (3-{3-[(4-Isopropyl-benzyl)-((R)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-acetic acid; 2-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-propane-1,3-diol; *N*-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-

diphenylethyl-amino]-propoxy}-phenyl)-carbamic acid tert-butyl ester; 3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethylamino]-propoxy}-phenylamine; *N*-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-acetamide; Furan-2-carboxylic acid *N*-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-amide; *N*-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-methanesulfonamide; *N*-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-benzenesulfonamide; 1-(2-Chloro-phenyl)-3-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-urea; *N*-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-*N*-methyl-amine; *N*-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-*N*-methyl-acetamide; Furan-2-carboxylic acid *N*-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-*N*-methyl-amide; *N*-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-*N*-methyl-methanesulfonamide; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-*N*-methyl-benzenesulfonamide; 3-(2-Chloro-phenyl)-1-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-1-methyl-urea; Benzo[1,3]dioxole-5-carboxylic acid *N*-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-*N*-methyl-amide; 1-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-3-(3,5-dimethoxy-phenyl)-1-methyl-urea; Propane-1-sulfonic acid (5-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-2-methyl-phenyl)-amide; 3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-2-methyl-phenylamine; 2-Chloro-5-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenylamine; 3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-cyclopentyl-amine, (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-isopropyl-amine, Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-ethyl-amine, (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-(3-methyl-butyl)-amine, (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-isobutyl-amine, (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-(2,2,2-trifluoroethyl)-amine, (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-cyclopropylmethy-l-amine, (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-(2-ethyl-butyl)-amine, (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-(2,2-dimethyl-propyl)-amine, (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-hexyl-amine, Butyl-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-amine, [1-(3-{3-[(2-Chloro-3-(trifluoromethyl)-benzyl)-(2,2-diphenylethyl)-amino]-propoxy}-phenyl-piperidine-4-carboxylic acid, [1-(3-{3-[(2-Chloro-3-(trifluoromethyl)-benzyl)-(2,2-diphenylethyl)-amino]-propoxy}-phenyl-piperidine-4-yl-acetic acid; [4-(3-{3-[(2-Chloro-3-(trifluoromethyl)-benzyl)-(2,2-diphenylethyl-amino]-propoxy}-phenyl)-piperidin-1-yl]-acetic acid, *rac*-±-(3-{3-[(2-

Chloro-3-trifluoromethyl-benzyl)-(trifluoro-phenyl-propyl)-amino]-propoxy}-phenyl)-acetic acid; *rac*-±-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2-dimethylamino-2-phenyl-ethyl)-amino]-propoxy}-phenyl)-acetic acid; *rac*-±-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2-morpholin-4-yl-2-phenyl-ethyl)-amino]-propoxy}-phenyl)-acetic acid; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(6-morpholin-4-yl-pyridin-2-yloxy)-propyl]-amine; [3-(6-Chloro-pyridin-2-yloxy)-propyl]-(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[6-(4-methyl-piperazin-1-yl)-pyridin-2-yloxy]-propyl}-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(6-piperazin-1-yl-pyridin-2-yloxy)-propyl]-amine; [4-(6-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)- amino]-propoxy}-pyridin-2-yl)-piperazin-1-yl]-acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl]((*S*)-2-phenyl-propyl)amino]- (*R*)-1-methyl-propoxy}-phenyl)acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl]((*S*)-2-phenyl-propyl)amino]- (*R*)-1-methyl-propoxy}-phenyl) ethanol; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl]((*S*)-2-phenyl-propyl)amino]- (*R*)-2-methyl-propoxy}-phenyl)acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl]((*S*)-2-phenyl-propyl)amino]- (*R*)-2-methyl-propoxy}-phenyl) ethanol; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl]((*R*)-2-phenyl-propyl)amino]- (*R*)-2-methyl-propoxy}-phenyl)acetic acid; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl]((*R*)-2-phenyl-propyl)amino]- (*R*)-2-methyl-propoxy}-phenyl)ethanol; (*R*)-2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-2-methyl-propoxy}-phenyl)ethanol; 3-{3-[(3-Chloro-2-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy-*N*,*N*-dimethyl-benzenesulfonamide, Cyclopropanecarboxylic acid 3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-benzylamide; N -(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-benzyl)-isobutyramide; Acetic acid (3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-benzylcarbamoyl)-methyl ester; N- -(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-benzyl)-propionamide; 2,5-Dimethyl-2-H -pyrazole-3-carboxylic acid 3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-benzylamide; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-(3-*o*-tolyloxy-propyl)-amine; 2-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-benzonitrile; 3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-benzonitrile; [3-(3-Chloro-phenoxy)-propyl]-(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(2-methoxy-phenoxy)-propyl]-amine; [3-(2-Chloro-phenoxy)-propyl]-(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-(3-phenoxy-propyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-isopropyl-phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(4-methoxy-phenoxy)-propyl]-amine; 3-{3-[(Chloro-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenol; 2-{3-[(Chloro-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenol; 3-{3-[(Chloro-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenylamine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-trifluoromethyl-phenoxy)-propyl]-amine;

1-(3-{3-[(Chloro-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethanone; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-phenyl-amine; [3-(Benzo[1,3]dioxol-5-yloxy)-propyl]-(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-(3-*m*-tolyloxy-propyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-methoxy-phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-isobutyl-phenoxy)-propyl]-amine; [3-(3-Butyl-phenoxy)-propyl]-(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-{3-[3-(2,2-dimethyl-propyl)-phenoxy]-propyl}-(2,2-diphenyl-ethyl)-amine; (4-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-benzyl)-methyl-amine; (2-Chloro-3-trifluoromethyl-benzyl)-[3-(4-dimethylaminomethyl-phenoxy)-propyl]-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(4-morpholin-4-ylmethyl-phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[4-(4-methyl-piperazin-1-ylmethyl)-phenoxy]-propyl}-amine; (3-{3-[(Chloro-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-benzyl)-methyl-amine; (2-Chloro-3-trifluoromethyl-benzyl)-[3-(3-dimethylaminomethyl-phenoxy)-propyl]-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-morpholin-4-ylmethyl-phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-piperazin-1-ylmethyl)-phenoxy]-propyl}-amine; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-benzyl)-isopropyl-amine; {3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-4-trifluoromethyl-phenylamine; {3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-4-methyl-phenylamine; Ethanesulfonic acid (3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-4-methyl-phenyl)-amide; Propane-2-sulfonic acid (3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-4-methyl-phenyl)-amide; Methanesulfonic acid (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-4-methyl-phenyl)-amide; 2,2,2-Trifluoro-ethanesulfonic acid (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-4-methyl-phenyl)-amide; Ethanesulfonic acid (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-phenyl)-amide; 2,2,2-Trifluoro-ethanesulfonic acid (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-phenyl)-amide; *N*-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-phenyl)-1,1,1-trifluoro-methanesulfonamide; Propane-2-sulfonic acid (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-phenyl)-amide; {3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-4-methoxy-phenylamine; Ethanesulfonic acid (3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl-amino)]-propoxy}-4-methoxy-phenyl)-amide; (2-Chloro-3-trifluoromethyl-benzyl)-{3-[3-(2-morpholin-4-yl-ethyl)-phenoxy]-propyl}-((S)-2-phenyl-propyl amine; (2-Chloro-3-trifluoromethyl-benzyl)-{3-[3-(2-ethylamino-ethyl)-phenoxy]-propyl}-((S)-2-phenyl-propyl)-amine; (3-{(R)-3-[(2-Chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-butoxy}-phenyl)-acetic acid; (3-{(S)-3-[(2-Chloro-3-

trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-butoxy}-phenyl)-acetic acid; 2-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-ethanol; 2-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-2-methyl-propionic acid; 2-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-((R)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-2-methyl-propionic acid; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2-thiophen-3-yl-propyl)-amino]-propoxy}-phenyl)-acetic acid; 2-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2-thiophen-3-yl-propyl)-amino]-propoxy}-phenyl)-ethanol; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2-thiophen-2-yl-propyl)-amino]-propoxy}-phenyl)-acetic acid; (3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2-pyridin-2-yl-propyl)-amino]-propoxy}-phenyl)-acetic acid; [3-(3-{(2-Chloro-3-trifluoromethyl-benzyl)-[2-(4-methyl-pyridin-2-yl)-propyl]-amino}-propoxy)-phenyl]-acetic acid; [3-(3-{(2-Chloro-3-trifluoromethyl-benzyl)-[3,3,3-trifluoro-2-(1*H* -pyrrol-2-yl)-propyl]-amino}-propoxy) -phenyl]-acetic acid; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-(3-{3-[2-(4-methyl-piperazin-1-yl)-ethyl]-phenoxy}-propyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(2-methylamino-ethyl)-phenoxy]-propyl}-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-{2-[(1H-imidazol-2-ylmethyl)-amino] -ethyl}-phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(2-ethylamino-ethyl)-phenoxy]-propyl}-amine; [3-(3-{2-[(5-Bromo-thiophen-2-ylmethyl)-amino]-ethyl}-phenoxy)-propyl]-(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-{2-[(thiophen-2-ylmethyl)-amino]-ethyl}-phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-{3-[3-(2-dimethylamino-ethyl)-phenoxy]-propyl}-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(2-pyrrolidin-1-yl-ethyl)-phenoxy]-propyl}-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(2-morpholin-4-yl-ethyl)-phenoxy] -propyl}-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{(R)-1-methyl-3-[3-(2-morpholin-4-yl-ethyl) -phenoxy]-propyl}-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{(R)-2-methyl-3-[3-(2-morpholin-4-yl-ethyl) -phenoxy]-propyl}-amine; {3-[3-(2-Amino-ethyl)-phenoxy]-propyl}-(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amine; [2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethyl]-isopropyl-amine; [2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethyl]-propyl-amine; 2-[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethylamino]-ethanol; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-{2-[(1-methyl-1H-imidazol-2-ylmethyl)-amino]-ethyl}-phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(2-thiomorpholin-4-yl-ethyl)-phenoxy] -propyl}-amine; [2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethylamino]-acetic acid; [2-(3-{(R)-3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-butoxy}-phenyl)-ethylamino]-acetic acid; {[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethyl]-methyl-amino}-acetic acid; 2-[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethylamino]-2-methyl-propionic acid; (S)-2-[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-

diphenylethyl-amino]-propoxy}-phenyl)-ethylamino]-propionic acid; (R)-1-[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethyl]-pyrrolidine-2-carboxylic acid; (S)-1-[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethyl]-pyrrolidine-2-carboxylic acid; [2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethyl]-pyrimidin-2-yl-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-morpholin-4-yl-phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-piperidin-1-yl-phenoxy)-propyl]-amine; (3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-diethyl-amine; (2-Chloro-3-trifluoromethyl-benzyl)-{3-[3-(2,5-dimethyl-pyrrol-1-yl)-phenoxy]-propyl}-(2,2-diphenyl-ethyl)-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-piperazin-1-yl-phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-[3-(3-piperazin-1-yl-phenoxy)-propyl]-amine; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[(R)-2-methyl-3-(3-piperazin-1-yl-phenoxy)- propyl]-amine, (2-Chloro-3-trifluoromethyl-benzyl)-isobutyl-[3-(3-piperazin-1-yl-phenoxy)-propyl]-amine; [4-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-piperazin-1-yl]-acetic acid; [4-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-piperazin-1-yl]-acetic acid; [4-(3-{(R)-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-methyl-propoxy}-phenyl)-piperazin-1-yl]-acetic acid; [4-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-isobutyl-amino]-propoxy}-phenyl)-piperazin-1-yl]-acetic acid; (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-piperazin-1-yl)-phenoxy]-propyl}-amine, (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-pyrrolidin-1-yl-phenoxy)-propyl]-amine; (3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenylamino)-acetic acid; [(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-*N*-methyl-amino]-acetic acid; N-(2,2-Diphenylethyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-[3-(2-methyl-2-aminopropyl)phenoxy]propylamine, N-(2,2-Diphenylethyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-[2-hydroxymethyl]phenoxy)propylamine, N-(2,2-Diphenylethyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-[2-hydroxy-2-methylpropyl]phenoxy)propylamine; N-(2,2-Diphenylethyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-N-methylsulfonamidophenoxy)propylamine, N-(2-[2-Chlorophenyl]-propyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine, N-(2-[3-Chlorophenyl]-propyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine, N-(2-[4-Chlorophenyl]-propyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine, N-(2-[2-Methoxyphenyl]-propyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine, N-(2-[4-Methoxyphenyl]-propyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine, N-(2-Phenyl-4-methylpentyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine, N-(2-Phenylbutyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine, N-(2-[2-Methyl-2-phenyl]propyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-

carboxymethylenephenoxy)propylamine, N-(2-Phenyl-3-methylbutyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine, N-(2-Phenylhexyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine, N-(2-Phenyl-3-butynyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine; (S)-N-(2-Phenyl-2-methoxyethyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine, (R)-N-(2-Phenyl-2-methoxyethyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine, (R)-N-(2-Phenyl-2-methoxyethyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-[2-hydroxy-2-methylpropyl]phenoxy)propylamine; 2-(3-{3-[[2-Chloro-3-(trifluoromethyl)benzyl](2-methyl-propyl)amino]-propoxy}-phenyl)acetic acid; 1-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-cyclobutanecarboxylic acid; 1-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-cyclopentanecarboxylic acid; 1-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-cyclopropanecarboxylic acid;

and a stereoisomer, a stereoisomeric mixture or racemate thereof and a pharmaceutically acceptable salt or solvate thereof.

20. The compound according to claim 19, selected from:

2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-dephenylethyl)amino]propoxy}phenyl)-ethanol,

(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenylethyl)-{3-[3-(1,2,4-triazol-3-ylmethyl)-phenoxy]-propyl}-amine,

(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(1,2,3,4-tetrazol-5-ylmethyl)-phenoxy]-propyl}-amine,

(2-chloro-3-trifluoromethyl-benzyl)-(2-cyclohexyl-2-phenyl-ethyl)-{3-[3-(1,2,3,4-tetrazol-5-ylmethyl)-phenoxy]-propyl}-amine,

(*S*)-(2-chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-{3-[3-(1,2,3,4-tetrazol-3-ylmethyl)-phenoxy]-propyl}-amine,

(*R*)-(2-chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-{3-[3-(1,2,3,4-tetrazol-3-ylmethyl)-phenoxy]-propyl}-amine,

2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl]-benzylamino]propoxy}-phenyl)acetic acid,

2-(3-{3-[[2-chloro-3-(trifluoromethyl)-benzyl]phenethylamino]propoxy}-phenyl)acetic acid,

2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-hydroxy-2-phenyl-ethyl)amino]propoxy}-phenyl)acetic acid,

2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-acetoxy-2-phenyl-ethyl)amino]propoxy}-phenyl)acetic acid,

2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-phenoxy-2-phenyl-ethyl)amino]propoxy}-phenyl)acetic acid,

(3-{3-[(2-acetoxy-2-phenyl-ethyl)-(2-chloro-3-trifluoromethyl-benzyl)-amino]-propoxy}-phenyl)-acetic acid methyl ester,

benzoic acid 2-[3-(3-methoxycarbonylmethyl-phenoxy){2-chloro-3-(trifluoromethyl)benzyl}propylamino]-1-phenyl ethyl ester,

(3-{4-[(2-chloro-3-(trifluoromethyl)benzyl)-(2,2-diphenylethyl)-amino]butyl}phenyl)-acetic acid,

2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-dephenylethyl)amino]propoxy}phenyl)-ethanol,

(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenylethyl)-{3-[3-(1,2,4-triazol-3-ylmethyl)-phenoxy]-propyl}-amine,

(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(1,2,3,4-tetrazol-5-ylmethyl)-phenoxy]-propyl}-amine,

(*S*)-(2-chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-{3-[3-(1,2,3,4-tetrazol-3-ylmethyl)-phenoxy]-propyl}-amine,

(*R*)-(2-chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-{3-[3-(1,2,3,4-tetrazol-3-ylmethyl)-phenoxy]-propyl}-amine,

(*S*)-2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-phenyl-propyl)amino]propoxy}-phenyl)acetic acid,

furan-2-carboxylic acid *N*-(3-{3-[(2-Chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-amide,

(*R*)-2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-phenyl-propyl)amino]propoxy}-phenyl)acetic acid,

2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-acetoxy-2-phenyl-ethyl)amino]propoxy}-phenyl)acetic acid,

(3-{3-[(2-acetoxy-2-phenyl-ethyl)-(2-chloro-3-trifluoromethyl-benzyl)-amino]-propoxy}-phenyl)-acetic acid methyl ester,

(3-{4-[(2-chloro-3-(trifluoromethyl)benzyl)-(2,2-diphenylethyl)-amino]butyl}phenyl)-acetic acid,

1-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-cyclobutanecarboxylic acid,

N-(2,2-diphenylethyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-[2-hydroxy-2-methylpropyl]phenoxy)propylamine,

(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-{2-[(1H-imidazol-2-ylmethyl)-amino] -ethyl}-phenoxy)-propyl]-amine,

N-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-methanesulfonamide,

N-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-*N*-methyl-amine,

[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethylamino]-acetic acid,

(R)-1-[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethyl]-pyrrolidine-2-carboxylic acid,

N-(2-[3-chlorophenyl]-propyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine,

(2-chloro-3-trifluoromethyl-benzyl)-{3-[3-(2-morpholin-4-yl-ethyl)-phenoxy]-propyl}-((S)-2-phenyl-propyl amine,

[4-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-piperazin-1-yl]-acetic acid,

2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-2-methyl-propionic acid,

(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-piperazin-1-yl)-phenoxy]-propyl}-amine,

(3-{(R)-3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-butoxy}-phenyl)-acetic acid,

[1-(3-{3-[(2-chloro-3-(trifluoromethyl)-benzyl)-(2,2-diphenylethyl)-amino]-propoxy}-phenyl-piperidine-4-carboxylic acid,

[4-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-piperazin-1-yl]-acetic acid,

[4-(3-{(R)-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-methyl-propoxy}-phenyl)-piperazin-1-yl]-acetic acid,

and a stereoisomer, a stereoisomeric mixture or racemate thereof and a pharmaceutically acceptable salt or solvate thereof.

21. The compound according to claim 1, wherein W^1 and W^2 are not each independently C_3-C_8 cycloalkyl or aryl or W^3 is not H or any one of R^6 or R^7 is not H or R^8 and R^9 are each C_1-C_4 alkyl when:

X is $COOR^{10}$;

Z is CH or CR^3 and k is 0-4 or Z is N and k is 0-3;

p is 0-8;

n is 2-8;

q is 0 or 1;

Q is selected from optionally unsubstituted or substituted C_3-C_8 cycloalkyl, phenyl and monocyclic Het;

each R^1 and R^2 is independently selected from H, C_1-C_6 alkyl, -OH, -O-C_1-C_6 alkyl, -SH, and -S-C_1-C_6 alkyl; and

each R^3 is the same or different and is independently selected from halo, cyano, nitro, $-CONR^{12}R^{13}$, $-COR^{14}$, $-SR^{11}$, $-SO_2R^{11}$, $-SOR^{14}$, $-OCOR^{14}$ and optionally unsubstituted or substituted C_1-C_6 alkyl, C_3-C_6 alkenyl, -5-6 membered-Het, -C_0-C_6 alkyl-CO_2R^{11}, or -C_0-C_6 alkyl-$NR^{12}R^{13}$.

22. A pharmaceutical composition comprising a compound according to any one of claims 1-21.

23. The pharmaceutical composition according to claim 22 further comprising a pharmaceutically acceptable carrier or diluent.

24. A method for the prevention or treatment of an LXR mediated disease or condition comprising administering a therapeutically effective amount of a compound having Formula I-A:



I-A

wherein:

X is selected from C_1-C_8 alkyl, halo, -OR^{10}, -$NR^{14}R^{15}$, nitro, cyano, -$COOR^{10}$, -COR^{13}, -$OCOR^{13}$, -$N(R^{17})COR^{13}$, -$N(R^{17})CONR^{14}R^{15}$, -$N(R^{17})COOR^{13}$, -SO_3H, -$SO_2NR^{14}R^{15}$, -$C(=NR^{17})NR^{14}R^{15}$, -$N(R^{17})SO_2R^{16}$, and a 5 or 6-membered heterocyclic group;

or X and an adjacent R^3, taken together with the atoms to which they are bonded, form an alkylenedioxy moiety;

Z is CH, CR^3 or N, wherein when Z is CH or CR^3, k is 0-4 and t is 0 or 1, and when Z is N, k is 0-3 and t is 0;

Y is selected from -O-, -S-, -$N(R^{10})$-, and -$C(R^4)(R^5)$-;

W^1 is selected from C_1-C_6 alkyl, C_3-C_8 cycloalkyl, aryl and Het, wherein said C_1-C_8 alkyl, C_3-C_8 cycloalkyl, Ar and Het are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-CO_2R^{10}, -C_0-C_6 alkyl-$C(O)SR^{10}$, -C_0-C_6 alkyl-$CONR^{11}R^{12}$, -C_0-C_6 alkyl-COR^{13}, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-SR^{10}, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-SO_3H, -C_0-C_6 alkyl-$SO_2NR^{11}R^{12}$, -C_0-C_6 alkyl-SO_2R^{10}, -C_0-C_6 alkyl-SOR^{13}, -C_0-C_6 alkyl-$OCOR^{13}$, -C_0-C_6 alkyl-$OC(O)NR^{11}R^{12}$, -C_0-C_6 alkyl-$OC(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)NR^{11}R^{12}$, and -C_0-C_6 alkyl-$NR^{11}COR^{13}$, where said C_1-C_6 alkyl, is optionally unsubstituted or substituted by one or more halo substituents;

W^2 is selected from H, halo, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-SR^{10}, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-CO_2R^{10}, -C_0-C_6 alkyl-$C(O)SR^{10}$, -C_0-C_6 alkyl-$CONR^{11}R^{12}$, -C_0-C_6 alkyl-COR^{13}, -C_0-C_6 alkyl-$OCOR^{13}$, -C_0-C_6 alkyl-$OCONR^{11}R^{12}$, -C_0-C_6 alkyl-$NR^{11}CONR^{11}R^{12}$, -C_0-C_6 alkyl-$NR^{11}COR^{13}$, -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-Ar and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl, wherein said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents, and wherein the C_3-C_7 cycloalkyl, Ar and Het moieties of said -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-Ar and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-CO_2R^{10}, -C_0-C_6 alkyl-$C(O)SR^{10}$, -C_0-C_6 alkyl-$CONR^{11}R^{12}$, -C_0-C_6 alkyl-COR^{13}, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-SR^{10}, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-SO_3H, -C_0-C_6 alkyl-$SO_2NR^{11}R^{12}$, -C_0-C_6 alkyl-SO_2R^{10}, -C_0-C_6 alkyl-SOR^{13}, -C_0-C_6 alkyl-$OCOR^{13}$, -C_0-C_6 alkyl-$OC(O)NR^{11}R^{12}$, -C_0-C_6 alkyl-$OC(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)NR^{11}R^{12}$, and -C_0-C_6 alkyl-$NR^{11}COR^{13}$, where said C_1-C_6 alkyl, is optionally unsubstituted or substituted by one or more halo substituents;

W^3 is selected from the group consisting of: H, halo, C_1-C_6 alkyl, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-SR^{10}, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-CO_2R^{10}, -C_0-C_6 alkyl-$C(O)SR^{10}$, -C_0-C_6 alkyl-$CONR^{11}R^{12}$, -C_0-C_6 alkyl-COR^{13}, -C_0-C_6 alkyl-$OCOR^{13}$, -C_0-C_6 alkyl-$OCONR^{11}R^{12}$, -C_0-C_6 alkyl-$NR^{11}CONR^{11}R^{12}$, -C_0-C_6 alkyl-$NR^{11}COR^{13}$, -C_0-C_6 alkyl-Het, -C_1-C_6 alkyl-Ar and -C_1-C_6 alkyl-C_3-C_7 cycloalkyl, wherein said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents;

Q is selected from C_3-C_8 cycloalkyl, Ar and Het; wherein said C_3-C_8 cycloalkyl, Ar and Het are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-CO_2R^{10}, -C_0-C_6 alkyl-$C(O)SR^{10}$, -C_0-C_6 alkyl-$CONR^{11}R^{12}$, -C_0-C_6 alkyl-COR^{13}, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-SR^{10}, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-SO_3H, -C_0-C_6 alkyl-$SO_2NR^{11}R^{12}$, -C_0-C_6 alkyl-SO_2R^{10}, -C_0-C_6 alkyl-SOR^{13}, -C_0-C_6 alkyl-$OCOR^{13}$, -C_0-C_6 alkyl-$OC(O)NR^{11}R^{12}$, -C_0-C_6 alkyl-$OC(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)NR^{11}R^{12}$, and -C_0-C_6 alkyl-$NR^{11}COR^{13}$, where said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents;

p is 0-8;

n is 2-8;

m is 0 or 1;

q is 0 or 1;

t is 0 or 1;

each R^1 and R^2 are independently selected from H, halo, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-SR^{10}, -C_1-C_6 alkyl-Het, -C_1-C_6 alkyl-Ar and -C_1-C_6 alkyl-C_3-C_7 cycloalkyl, or R^1 and R^2 together with the carbon to which they are attached form a 3-5 membered carbocyclic or heterocyclic ring, wherein said

heterocyclic ring contains one, or more heteroatoms selected from N, O, and S, where any one of said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each R^3 is the same or different and is independently selected from halo, cyano, nitro, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-Ar, -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-C_3-C_7 cycloalkyl, -C_0-C_6 alkyl-CO_2R^{10}, -C_0-C_6 alkyl-$C(O)SR^{10}$, -C_0-C_6 alkyl-$CONR^{11}R^{12}$, -C_0-C_6 alkyl-COR^{13}, -C_0-C_6 alkyl-$NR^{11}R^{12}$, -C_0-C_6 alkyl-SR^{10}, -C_0-C_6 alkyl-OR^{10}, -C_0-C_6 alkyl-SO_3H, -C_0-C_6 alkyl-$SO_2NR^{11}R^{12}$, -C_0-C_6 alkyl-SO_2R^{10}, -C_0-C_6 alkyl-SOR^{13}, -C_0-C_6 alkyl-$OCOR^{13}$, -C_0-C_6 alkyl-$OC(O)NR^{11}R^{12}$, -C_0-C_6 alkyl-$OC(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)OR^{13}$, -C_0-C_6 alkyl-$NR^{11}C(O)NR^{11}R^{12}$, and -C_0-C_6 alkyl-$NR^{11}COR^{13}$, wherein said C_1-C_6 alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each R^4 and R^5 is independently selected from H, halo, C_1-C_6 alkyl, -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-Ar and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl;

R^6 and R^7 are each independently selected from H, halo, C_1-C_6 alkyl, -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-Ar and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl;

R^8 and R^9 are each independently selected from H, halo, C_1-C_6 alkyl, -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-Ar and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl;

R^{10} is selected from H, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-Ar, -C_0-C_6 alkyl-Het and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl;

each R^{11} and each R^{12} are independently selected from H, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-Ar, -C_0-C_6 alkyl-Het and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl, or R^{11} and R^{12} together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S;

R^{13} is selected from C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-Ar, -C_0-C_6 alkyl-Het and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl;

R^{14} and R^{15} are each independently selected from H, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, -C_0-C_6 alkyl-Ar, -C_0-C_6 alkyl-Het, -C_0-C_6 alkyl-C_3-C_7 cycloalkyl, -C_0-C_6 alkyl-O-Ar, -C_0-C_6 alkyl-O-Het, -C_0-C_6 alkyl-O-C_3-C_7 cycloalkyl, -C_0-C_6 alkyl-$S(O)_x$-C_1-C_6 alkyl, -C_0-C_6 alkyl-$S(O)_x$-Ar, -C_0-C_6 alkyl-$S(O)_x$-Het, -C_0-C_6 alkyl-$S(O)_x$-C_3-C_7 cycloalkyl, -C_0-C_6 alkyl-NH-Het, -C_0-C_6 alkyl-NH-C_3-C_7 cycloalkyl, -C_0-C_6 alkyl-N(C_1-C_4 alkyl)-Ar, -C_0-C_6 alkyl-N(C_1-C_4 alkyl)-Het, -C_0-C_6 alkyl-N(C_1-C_4 alkyl)-C_3-C_7 cycloalkyl, -C_0-C_6 alkyl-Ar, -C_0-C_6 alkyl-Het and -C_0-C_6 alkyl-C_3-C_7 cycloalkyl, where x is 0, 1 or 2, or R^{14} and R^{15}, together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S, wherein said C_1-C_6 alkyl is optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, $-NH_2$, -NH(unsubstituted C_1-C_6 alkyl), -N(unsubstituted C_1-C_6 alkyl)(unsubstituted C_1-C_6 alkyl), unsubstituted -OC_1-C_6 alkyl, $-CO_2H$,

$-CO_2$(unsubstituted C_1-C_6 alkyl), $-CONH_2$, -CONH(unsubstituted C_1-C_6 alkyl), -CON(unsubstituted C_1-C_6 alkyl)(unsubstituted C_1-C_6 alkyl), $-SO_3H$, $-SO_2NH_2$, $-SO_2NH$(unsubstituted C_1-C_6 alkyl) and $-SO_2N$(unsubstituted C_1-C_6 alkyl)(unsubstituted C_1-C_6 alkyl);

R^{16} is C_1-C_6 alkyl, $-C_0$-C_6 alkyl-Ar or $-C_0$-C_6 alkyl-Het; and

R^{17} is H, C_1-C_6 alkyl, $-C_0$-C_6 alkyl-Ar or $-C_0$-C_6 alkyl-Het;

provided that X is not $COOR^{10}$ when Y is -O-, p is 0-8, n is 2-8, m is 1, q is 0 or 1, t is 0, each R^1 and R^2 is independently selected from H, C_1-C_6 alkyl, -OH, -O-C_1-C_6 alkyl, -SH, and -S-C_1-C_6 alkyl, each R^4, R^5, R^6, R^7, R^8 and R^9 are independently H or C_1-C_4 alkyl, k is 0 or 1, W^3 is H, W^1 and W^2 are each independently selected from C_3-C_8 cycloalkyl and aryl and R^3 and Q are as defined above;

or a pharmaceutically acceptable salt or solvate thereof.

25. The method according to claim 24, wherein R^1 and R^2 are independently H or C_1-C_4 alkyl or R^1 and R^2 together with the carbon to which they are attached form a 3-5 membered carbocyclic ring.

26. The method according to claim 24 or 25, wherein X is selected from C_1-C_6 alkyl, halo, $-OR^{10}$, $-NR^{14}R^{15}$, cyano, $-COR^{13}$, $-COOR^{10}$, $-OCOR^{13}$, $-N(R^{17})CONR^{14}R^{15}$, $-N(R^{17})COR^{13}$, $-SO_2NR^{14}R^{15}$, $-N(R^{17})SO_2R^{16}$, and a 5 or 6-membered heterocyclic group or X and an adjacent R^3, taken together with the atoms to which they are bonded, form an alkylenedioxy moiety.

27. The method according to any claim 26, wherein R^{10} is H, C_1-C_4 alkyl or phenyl; R^{13} is H, C_1-C_4 alkyl, $-C_0$-C_4 alkyl-C_3-C_7 cycloalkyl, or $-C_0$-C_4 alkyl-phenyl; R^{14} and R^{15} are each independently selected from H, C_1-C_6 alkyl, $-C_0$-C_4 alkyl-Ar, $-C_0$-C_4 alkyl-Het, $-C_0$-C_4 alkyl-C_3-C_7 cycloalkyl, $-C_0$-C_4 alkyl-O-Ar, $-C_0$-C_4 alkyl-O-Het, $-C_0$-C_4 alkyl-O-C_3-C_7 cycloalkyl, $-C_0$-C_4 alkyl-$S(O)_2$-C_1-C_4 alkyl, $-C_0$-C_4 alkyl-$S(O)_2$-Ar, $-C_0$-C_4 alkyl-$S(O)_2$-Het, $-C_0$-C_4 alkyl-$S(O)_2$-C_3-C_7 cycloalkyl, $-C_0$-C_4 alkyl-NH-Ar, $-C_0$-C_4 alkyl-NH-Het, $-C_0$-C_4 alkyl-NH-C_3-C_7 cycloalkyl, $-C_0$-C_4 alkyl-N(C_1-C_4 alkyl)-Ar, $-C_0$-C_4 alkyl-N(C_1-C_4 alkyl)-Het, $-C_0$-C_4 alkyl-N(C_1-C_4 alkyl)-C_3-C_7 cycloalkyl, $-C_0$-C_4 alkyl-Ar, $-C_0$-C_4 alkyl-Het and $-C_0$-C_4 alkyl-C_3-C_7 cycloalkyl, or R^{14} and R^{15}, together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S, wherein said C_1-C_6 alkyl is optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, $-NH_2$, -NH(unsubstituted C_1-C_4 alkyl), -N(unsubstituted C_1-C_4 alkyl)(unsubstituted C_1-C_4 alkyl), unsubstituted $-OC_1$-C_4 alkyl, $-CO_2H$, $-CO_2$(unsubstituted C_1-C_4 alkyl), $-CONH_2$, -CONH(unsubstituted C_1-C_4 alkyl), -CON(unsubstituted C_1-C_4 alkyl)(unsubstituted C_1-C_4 alkyl), $-SO_3H$, $-SO_2NH_2$,

-SO_2NH(unsubstituted C_1-C_4 alkyl) and -SO_2N(unsubstituted C_1-C_4 alkyl)(unsubstituted C_1-C_4 alkyl); R^{16} is C_1-C_4 alkyl or phenyl; and R^{17} is H or C_1-C_4 alkyl.

28. The method according to any one of claims 24-27 wherein n is 3.

29. The method according to any one of claims 24-28, wherein Q is a substituted or unsubstituted phenyl or furanyl group or a benzo[1,3]dioxyl or benzo[1,4]dioxyl group containing one, two or three substituents selected from halo, C_1-C_4 alkyl; C_1-C_4 alkylthio; or -$NR^{Q1}R^{Q2}$, where R^{Q1} and R^{Q2} taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may optionally contain one or more additional heteroatoms selected form N, O and S.

30. The method according to any one of claims 24-29, wherein W^1 is phenyl, naphthyl, thienyl, pyridyl, furanyl, pyrrolyl, cyclohexyl, cyclopentyl, morpholinyl, or pyrrolidinyl, where each phenyl, naphthyl, thienyl, pyridyl, furanyl, pyrrolyl, cyclohexyl, cyclopentyl, morpholinyl, or pyrrolidinyl may be optionally substituted from 1 to 3 times with one or more of the substituents independently selected from C_1-C_4 alkyl, -OH, halo, -O-C_1-C_4 alkyl, and -C_1-C_4 haloalkyl.

31. The method according to any one of claims 24-30, wherein W^2 is C_1-C_4 alkyl, C_2-C_4 alkynyl, C_3-C_6 cycloalkyl, aryl, Het hydroxy, aryloxy-, C_1-C_4 alkoxy-, -OCOC_1-C_4 alkyl, -OCOaryl, or -$NR^{W1}R^{W2}$, where R^{W1} and R^{W2} are independently H or C_1-C_4 alkyl or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may optionally contain one or more additional heteroatoms selected form N, O and S.

32. The method according to claim 24, wherein X is selected from C_1-C_6 alkyl, halo, -OR^{10}, -$NR^{14}R^{15}$, cyano, -COR^{13}, -$COOR^{10}$, -$OCOR^{13}$, -$N(R^{17})CONR^{14}R^{15}$, -$N(R^{17})COR^{13}$, -$SO_2NR^{14}R^{15}$, -$N(R^{17})SO_2R^{16}$, and a 5 or 6-membered heterocyclic group or X and an adjacent R^3, taken together with the atoms to which they are bonded, form an alkylenedioxy moiety, where R^{10} is H, C_1-C_4 alkyl or phenyl, R^{13} is H, C_1-C_4 alkyl, -C_0-C_4 alkyl-C_3-C_7 cycloalkyl, or -C_0-C_4 alkyl-phenyl, R^{14} and R^{15} are each independently selected from H, C_1-C_6 alkyl, -C_0-C_4 alkyl-Ar, -C_0-C_4 alkyl-Het, -C_0-C_4 alkyl-C_3-C_7 cycloalkyl, -C_0-C_4 alkyl-O-Ar, -C_0-C_4 alkyl-O-Het, -C_0-C_4 alkyl-O-C_3-C_7 cycloalkyl, -C_0-C_4 alkyl-$S(O)_2$-C_1-C_4 alkyl, -C_0-C_4 alkyl-$S(O)_2$-Ar, -C_0-C_4 alkyl-$S(O)_2$-Het, -C_0-C_4 alkyl-$S(O)_2$-C_3-C_7 cycloalkyl, -C_0-C_4 alkyl-NH-Ar, -C_0-C_4 alkyl-NH-Het, -C_0-C_4 alkyl-NH-C_3-C_7 cycloalkyl, -C_0-C_4 alkyl-N(C_1-C_4 alkyl)-Ar, -C_0-C_4 alkyl-N(C_1-C_4 alkyl)-Het, -C_0-C_4 alkyl-N(C_1-C_4 alkyl)-C_3-C_7 cycloalkyl, -C_0-C_4 alkyl-Ar, -C_0-C_4 alkyl-Het and -C_0-C_4 alkyl-C_3-C_7 cycloalkyl, or R^{14} and R^{15}, together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring which optionally contains

one or more additional heteroatoms selected from N, O, and S, wherein said C_1-C_6 alkyl is optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, $-NH_2$, -NH(unsubstituted C_1-C_4 alkyl), -N(unsubstituted C_1-C_4 alkyl)(unsubstituted C_1-C_4 alkyl), unsubstituted -OC_1-C_4 alkyl, $-CO_2H$, $-CO_2$(unsubstituted C_1-C_4 alkyl), $-CONH_2$, -CONH(unsubstituted C_1-C_4 alkyl), -CON(unsubstituted C_1-C_4 alkyl)(unsubstituted C_1-C_4 alkyl), $-SO_3H$, $-SO_2NH_2$, $-SO_2$NH(unsubstituted C_1-C_4 alkyl) and $-SO_2$N(unsubstituted C_1-C_4 alkyl)(unsubstituted C_1-C_4 alkyl), R^{16} is C_1-C_4 alkyl or phenyl, and R^{17} is H or C_1-C_4 alkyl; p is 0, 1 or 2; R^1 and R^2 are independently H or C_1-C_4 alkyl or R^1 and R^2 together with the carbon to which they are attached form a 3-5 membered carbocyclic ring; k is 0 or k is 1 and R^3 is halo, C_1-C_4 alkyl or C_1-C_4 alkoxy; n is 3 and each R^4 and R^5 are independently selected from H and C_1-C_3 alkyl; Z is CH or N; Y is -O- or -C(R^4)(R^5)-; q is 1; R^8 and R^9 are each H; Q is a substituted or unsubstituted phenyl or furanyl group or a benzo[1,3]dioxyl or benzo[1,4]dioxyl group, where the substituted phenyl or furanyl group contains one, two or three substituents selected from halo, C_1-C_4 alkyl; C_1-C_4 alkylthio; or -$NR^{Q1}R^{Q2}$, where R^{Q1} and R^{Q2} taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may optionally contain one or more additional heteroatoms selected form N, O and S; t is 0 or 1; m is 0 or 1; R^6 and R^7 are independently selected from H and C_1-C_4 alkyl; W^1 is methyl, unsubstituted phenyl, naphthyl, pyridyl, thienyl or pyrrolyl or substituted phenyl or pyridyl containing one or two substituents independently selected from halo, alkyl and alkoxy, specifically, chloro, methyl and methoxy; W^2 is C_1-C_4 alkyl, C_2-C_4 alkynyl, C_3-C_6 cycloalkyl, aryl, Het hydroxy, aryloxy-, C_1-C_4 alkoxy-, -$OCOC_1$-C_4 alkyl, -OCOaryl, or -$NR^{W1}R^{W2}$, where R^{W1} and R^{W2} are independently H or C_1-C_4 alkyl or taken together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring, which may optionally contain one or more additional heteroatoms selected form N, O and S; W^3 is H or C_1-C_4 alkyl; or a pharmaceutically acceptable salt or solvate thereof.

33. The method according to claim 24, wherein X is chloro, bromo, cyano, carboxy-, methylcarboxy-, hydroxy, methoxy, methyl, trifluoromethyl, 1,3-dihydroxy-prop-2-yl (-$CH(CH_2OH)_2$,, isopropyl, n-butyl, isobutyl, 2,2-dimethylpropyl, phenylcarbonyl, triazolyl, tetrazolyl, $-NH_2$, $-NHCH_3$, $-NHCH_2CH_3$, $-NHCH_2CH_2CH_3$, $-NHCH_2CH_2CH_2CH_3$, $-NHCH_2CH_2CH_2CH_2CH_2CH_3$, $-NHCH_2C(CH_3)_3$, $-NHCH_2CH(CH_3)_2$, $-NHCH_2CH_2CH(CH_3)_2$, -NH-cyclopentyl, -NH-phenyl, $-NHCH_2$-cyclopropyl, $-NHCH(CH_3)_2$, $-NHCH_2CF_3$, $-N(CH_3)_2$, $-N(CH_2CH_3)_2$, $-NHCH(CH_2CH_3)_2$, $-NHCH_2CH(CH_2CH_3)_2$, $-NHCH_2CH_2OH$, $-NHCH_2CO_2H$, $-N(CH_3)CH_2CO_2H$, $-NHC(CH_3)_2CO_2H$, $-NHCH(CH_3)CO_2H$, -(R)-$NHCH(CH_3)CO_2H$, -(S)-$NHCH(CH_3)CO_2H$, $-NHCH_2$-1H-imidazol-2-yl, $-NHCH_2$-(1-CH_3-imidazol-2-yl, -NH-(pyrimidin-2-yl), -morpholin-4-yl, -thiomorpholin-4-yl, -piperidin-1-yl, -piperidin-1-yl-(4-carboxylic acid), -piperidin-1-yl-(4-acetic acid), -piperidin-4-yl-(1-acetic acid), -2,5-dimethyl-pyrrol-1-yl, -pyrrolidin-1-yl, -((R)-2-CO_2H-pyrrolidin-1-yl), -((S)-2-CO_2H-pyrrolidin-1-yl), -piperazin-1-yl, -(4-methyl-piperazin-1-yl),

-piperazin-1-yl-(4-acetic acid), -$NHCH_2$-(5-bromo-thien-2-yl), -$NHCH_2$-1H-imidazol-2-yl, -$NHCH_2$-(1-methyl-imidazol-2-yl, -$NHCOCH_3$, -$N(CH_3)COCH_3$, -$NHCO_2C(CH_3)_3$, -$NHCOCH_2CH_3$, -$NHCOC(CH_3)_2$, -NHCO-furan-2-yl, -$N(CH_3)$CO-furan-2-yl, -NHCO-thien-2-yl, -NHCO-cyclopropyl, -NHCO-(5-bromo-thien-2-yl, -NHCO-(2,5-dimethyl-pyrrol-3-yl), -$NHSO_2CH_3$, -$N(CH_3)SO_2CH_3$, -$NHSO_2CF_3$, -$NHSO_2$phenyl, -$N(CH_3)SO_2$phenyl, -$NHSO_2CH_2CH_3$, -$NHSO_2CH_2CF_3$, -$NHSO_2CH_2CH_2CH_3$, -$NHSO_2CH(CH_3)_2$,-NHCONH(2-chlorophenyl), -$N(CH_3)$CONH(3,5-dimethoxyphenyl), -$N(CH_3)$CONH(2-chlorophenyl), -$N(CH_3)$CO-(benzo[1,3]diox-5-yl), -SO_2NHCH_3, and -$SO_2N(CH_3)_2$; p is 0, 1 or 2; R^1 and R^2 are H C_1-C_4 alkyl or R^1 and R^2 together with the carbon to which they are attached form a 3, 4 or 5 membered carbocyclic ring; Z is CH of N; k is 0 or k is 1 and R^3 is methyl, trifluoromethyl, chloro or methoxy; n is 3 and R^4 and R^5 are independently selected from H and methyl; Y is -O- or -$C(R^4)(R^5)$-; q is 1; R^8 and R^9 are each H; Q is 2-chloro-3-(trifluoromethyl)phenyl, 3-methyl-4-fluoro-phenyl, 4-tert-butyl-phenyl, 4-(methylthio)phenyl, 2,4,5-trifluoro-phenyl, 4-isopropyl-phenyl, 5-(piperidin-1-yl)-furan-2-yl, benzo[1,3]diox-5-yl, or 2,3-dihydrobenzo[1,4]dioxin-6-yl; t is 0 or 1; m is 0 or 1; R^6 and R^7 are independently selected from H and methyl; W^1 is methyl, phenyl, naphth-1-yl, pyrid-2-yl, 4-methyl-pyrid-2-yl, thien-2-yl, thien-3-yl, pyrrol-2-yl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methoxyphenyl, or 4-methoxyphenyl; W^2 is methyl, ethyl, ethynyl, isopropyl, n-butyl, 2-methylpropyl, trifluorormethyl, cyclohexyl, unsubstituted phenyl, hydroxy, methoxy, phenoxy, dimethylamino, morpholin-4-yl, phenylcarbonyloxy, or methylcarbonyloxy; W^3 is H or methyl; or a pharmaceutically acceptable salt or solvate thereof.

34. The method according to claim 24, comprising administering a compound selected from:

2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-dephenylethyl)amino]propoxy}phenyl)-ethanol,

(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenylethyl)-{3-[3-(1,2,4-triazol-3-ylmethyl)-phenoxy]-propyl}-amine,

(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(1,2,3,4-tetrazol-5-ylmethyl)-phenoxy]-propyl}-amine,

(*S*)-(2-chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-{3-[3-(1,2,3,4-tetrazol-3-ylmethyl)-phenoxy]-propyl}-amine,

(*R*)-(2-chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-{3-[3-(1,2,3,4-tetrazol-3-ylmethyl)-phenoxy]-propyl}-amine,

(*S*)-2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-phenyl-propyl)amino]propoxy}-phenyl)acetic acid,

(*R*)-2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-phenyl-propyl)amino]propoxy}-phenyl)acetic acid,

2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2-acetoxy-2-phenyl-ethyl)amino]propoxy}-phenyl)acetic acid,

(3-{3-[(2-Acetoxy-2-phenyl-ethyl)-(2-chloro-3-trifluoromethyl-benzyl)-amino]-propoxy}-phenyl)-acetic acid methyl ester,

(3-{4-[(2-chloro-3-(trifluoromethyl)benzyl)-(2,2-diphenylethyl)-amino]butyl}phenyl)-acetic acid,

1-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-cyclobutanecarboxylic acid,

N-(2,2-diphenylethyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-[2-hydroxy-2-methylpropyl]phenoxy)propylamine,

(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-(3-{2-[(1H-imidazol-2-ylmethyl)-amino] -ethyl}-phenoxy)-propyl]-amine,

N-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-methanesulfonamide,

N-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-*N*-methyl-amine,

[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethylamino]-acetic acid,

(R)-1-[2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-ethyl]-pyrrolidine-2-carboxylic acid,

furan-2-carboxylic acid *N*-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-2,2-diphenylethyl-amino]-propoxy}-phenyl)-amide,

N-(2-[3-chlorophenyl]-propyl)-N-(2-chloro-3-trifluoromethylbenzyl)-3-(3-carboxymethylenephenoxy)propylamine,

(2-chloro-3-trifluoromethyl-benzyl)-{3-[3-(2-morpholin-4-yl-ethyl)-phenoxy]-propyl}-((S)-2-phenyl-propyl amine,

[4-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-propoxy}-phenyl)-piperazin-1-yl]-acetic acid,

2-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-2-methyl-propionic acid,

(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(4-methyl-piperazin-1-yl)-phenoxy]-propyl}-amine,

(3-{(R)-3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-butoxy}-phenyl)-acetic acid,

[1-(3-{3-[(2-chloro-3-(trifluoromethyl)-benzyl)-(2,2-diphenylethyl)-amino]-propoxy}-phenyl-piperidine-4-carboxylic acid,

[4-(3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-((S)-2-phenyl-propyl)-amino]-propoxy}-phenyl)-piperazin-1-yl]-acetic acid,

[4-(3-{(R)-[(2-chloro-3-trifluoromethyl-benzyl)-diphenylethyl-amino]-methyl-propoxy}-phenyl)-piperazin-1-yl]-acetic acid,

and a stereoisomer, a stereoisomeric mixture or racemate thereof and a pharmaceutically acceptable salt or solvate thereof.

35. The method according to any one of claims 24-34, wherein said LXR mediated disease or condition is cardiovascular disease.

36. The method according to any one of claims 24-35, wherein said LXR mediated disease or condition is atherosclerosis.

37. The method according to any one of claims 24-35, wherein said LXR mediated disease or condition is inflammation.

38. A method for increasing reverse cholesterol transport, said method comprising administering a therapeutically effective amount of the compound according to any one of claims any one of claims 1-21.

39. A method for inhibiting cholesterol absorption, said method comprising administering a therapeutically effective amount of the compound according to any one of claims any one of claims 1-21.

40. A compound according to any one of claims 1-21 for use as a medicament.

41. Use of a compound according to any one of claims 1-21 for the preparation of a medicament for the prevention or treatment of an LXR mediated disease or condition.

42. Use of a compound according to any one of claims 1-21 for the preparation of a medicament for the prevention or treatment of cardiovascular disease.

43. Use of a compound according to any one of claims 1-21 for the preparation of a medicament for the prevention or treatment of atherosclerosis.

44. Use of a compound according to any one of claims 1-21 for the preparation of a medicament for the prevention or treatment of inflammation.

45. Use of a compound according to any one of claims 1-21 for the preparation of a medicament for increasing reverse cholesterol transport.

46. Use of a compound according to any one of claims 1-21 for the preparation of a medicament for inhibiting cholesterol absorption.

47. A pharmaceutical composition comprising a compound according to any one of claims 1-21 for use in the prevention or treatment of an LXR mediated disease or condition.

48. A compound selected from the group:
{3-[4-(t-butyldimethylsilylhydroxy)but-1-ynyl]phenyl}acetic acid methyl ester,
{3-[4-hydroxybutyl]phenyl}acetic acid methyl ester,
{3-[4-(toluene-4-sulfonyloxy)butyl]phenyl}acetic acid methyl ester,
(*S*)-(2-chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-amine,
(*R*)-(2-chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-amine,
(2-chloro-3-trifluoromethyl-benzyl)-(naphthalene-1-ylmethyl)-amine,
(2-chloro-3-trifluoromethyl-benzyl)-(phenethyl)-amine,
(2-chloro-3-trifluoromethyl-benzyl)-(benzyl)-amine,
(2-chloro-3-trifluoromethyl-benzylamino)-phenyl-ethanol,
3-(3-benzyloxy-benzyl)-1,2,4-triazole,
3-(3-benzyloxy-benzyl)-ethoxymethyl-1,2,4-triazole,
[3-(ethoxymethyl)-1,2,4-triazol-3-ylmethyl]-phenol,
{3-[3-(3-bromo-propoxy)-benzyl]}-(ethoxymethyl)-1,2,4-triazole,
(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(ethoxymethyl)-1,2,4-triazol-3-ylmethyl-phenoxy]-propyl}-amine,
5-(3-benzyloxy-benzyl)-1,2,3,4-tetrazole,
5-(3-benzyloxy-benzyl)-ethoxymethyl-1,2,3,4-tetrazole,
5-(3-hydroxy-benzyl)-ethoxymethyl-1,2,3,4-tetrazole,
5-[3-(3-bromo-propoxy)-benzyl]-(ethoxymethyl)-1,2,3,4-tetrazole,
(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-{3-[3-(ethoxymethyl-1,2,3,4-tetrazol-5-ylmethyl)-phenoxy]-propyl}-amine,
or pharmaceutically acceptable salts or solvates thereof.